Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CFO John Maxim Ferrari sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $93.75, for a total transaction of $937,500.00. Following the sale, the chief financial officer now directly owns 407 shares in the company, valued at approximately $38,156. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

UTHR has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday. They now have a $112.00 price target on the stock. Separately, analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Finally, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. United Therapeutics currently has an average rating of “Buy” and an average price target of $102.87.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 0.41% on Friday, hitting $94.13. The stock had a trading volume of 362,885 shares. United Therapeutics has a 52 week low of $70.34 and a 52 week high of $116.65. The stock’s 50-day moving average is $91.46 and its 200-day moving average is $95.51. The company has a market cap of $4.449 billion and a P/E ratio of 18.12.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. On average, analysts predict that United Therapeutics will post $8.55 earnings per share for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.